Table 2 Per-protocol analysis results of PCR uncorrected pyronaridine–artesunate efficacy against P. vivax in Northwest Ethiopia
Treatment outcome | Value |
|---|---|
Early treatment failure, n (%) | 0 (0) |
Late clinical failure (N = 49), n (%) | 2 (4) |
Late parasitological failure, n (%) | 0 (0) |
Adequate clinical and parasitological response (N = 49), n (cumulative risk %a; 95% CI) | 47 (95.9; 84.9–99.0) |
Lost/withdrawn, n (%) | 2 (3.9) |
Total per protocol, n (%) | 49 (96.1) |